NervGen Pharma Corp.

This Spinal Cord Injury Awareness Month, we’re proud to highlight an important conversation with our CEO, Adam Rogers, MD, featured on the Progress, Potential, and Possibilities podcast with Ira S. Pastor. Adam shares insights on the urgent unmet need in spinal cord injury, where no approved pharmacologic treatments exist today, and discusses NervGen’s mission to transform the lives of individuals living with spinal cord injury. NervGen’s lead candidate, NVG-291, is the first pharmacologic candidate to demonstrate meaningful functional improvements in people living with spinal cord injury. Watch the full interview: https://lnkd.in/evQnR5sJ #SpinalCordInjuryAwarenessMonth #Neuroscience #Biotech #Innovation #Podcast

Today, on World Spinal Cord Injury Day, we recognize the challenges faced by the over 300,000 people living with SCI in the U.S. and the 18,000 new injuries each year—and we stand committed to driving change. For decades the medical community has been taught that when neurons in the central nervous system are damaged, repair is impossible. At NervGen, we know this is not true. Our scientific founder, Dr. Jerry Silver, spent his career disproving this narrative and created NVG-291, the first pharmacologic candidate designed to enable the nervous system to repair itself after spinal cord injury. This is science with a purpose. It’s about restoring independence and quality of life for those living with SCI. On this day, we stand with the community, honoring their resilience and working toward a future where repair and recovery are possible. Learn more about NervGen and NVG-291: https://nervgen.com/ #SCI #WorldSCIDay #SpinalCordInjury

NervGen today announced its second quarter 2025 financial results, including a letter to shareholders from Adam Rogers, MD, the Company’s Chairman and Interim Chief Executive Officer, providing a detailed business update. “The second quarter of 2025 marked a historic turning point for NervGen and the SCI community. After decades of virtually no therapeutic progress in spinal cord injury, we announced unprecedented topline results from our CONNECT SCI Study. We show for the first time that daily subcutaneous NVG-291 treatment, a pharmacologic candidate, significantly improved corticospinal connectivity and restored meaningful function for people with chronic SCI. These results represent both a scientific breakthrough and a pivotal step forward for the millions worldwide living with spinal cord injuries,” said Adam Rogers, MD, Interim Chief Executive Officer of NervGen. See the full release here:  https://lnkd.in/eauJnkr7 #SCI #SpinalCordInjury #News 

NervGen today announced positive preclinical results of two United States Department of Defense sponsored studies in models of blast-induced sensorineural hearing loss and peripheral nerve injury, reinforcing the broad therapeutic application of our first- and potential best-in-class candidate, NVG-291. These preclinical findings build on the recently announced CONNECT SCI Study topline results, the first proof-of-concept study to successfully demonstrate that pharmacological treatment with NVG-291 translates improvements observed in animal models into electrophysiological connectivity and clinically meaningful functional gains in individuals living with chronic spinal cord injury. See the full release here: https://lnkd.in/eSRFGtaN #SCI #SpinalCordInjury #News

NervGen announced the appointment of Randall Kaye, MD, to the role of Chief Medical Advisor. Dr. Kaye will expand his capacity as a member of NervGen’s Board of Directors and Chair of the Science Committee to medical advisor to the company. Read the full release: https://lnkd.in/gsrfe8KE #announcement #SCI #spinalcordinjury

“We achieved our primary endpoint demonstrating improved hand-motor connectivity and showed positive improvement in hand function in the chronic cohort of our Phase 1b/2a trial,” said Michael Kelly, NervGen’s President and Chief Executive Officer. Chief Medical Officer, Daniel Mikol MD, PhD, will present the positive study results in-person today at the @ASIA_spine 2025 Annual Scientific Meeting. Learn more: https://lnkd.in/etWNgNXq #SCI #clinicaltrial #ASIA2025 #ASIA2025SCIAnnualMeeting

Today, NervGen announced the results from the chronic cohort (1-10 years post-injury) of its Phase 1b/2a clinical trial evaluating its lead drug candidate, NVG-291, in spinal cord injury.     Read more about the results: https://lnkd.in/etWNgNXq      #announcement #trialresults #SCI #innovation 

At NervGen, the clinical trial for our lead drug candidate, NVG-291, has a unique design where we study connectivity using electrophysiology in partnership with the Shirley Ryan AbilityLab. Watch to learn more: https://lnkd.in/eQbB-uSZ #spincalcordinjury #science #innovation #clinicaltrial 

Did you know, in the U.S., spinal cord injury (#SCI) affects over 300,000 people and there are currently no approved drugs to enable sustained functional recovery?    At NervGen, we’re working to change that. Our lead drug candidate, NVG-291, is a first-in-class therapeutic peptide targeting mechanisms that interfere with nervous system repair.    Learn more about the science: https://lnkd.in/eXv4D7Bd   #spinalcordinjury #clinicaltrial #science #innovation

On Tuesday, June 3, Chief Medical Officer Daniel Mikol MD, PhD will present at the upcoming AMERICAN SPINAL INJURY ASSOCIATION 2025 Annual Scientific Meeting.    Learn more: https://lnkd.in/eqZeqtSc   #SCI #spinalcordinjury #clinicaltrial #ASIA2025SCIAnnualMeeting #ASIA2025Scottsdale #innovation